|
|
|
| The Anti-tumor Activity of Mycobacterium tuberculosis Heat Shock Protein 65 in B16-F10 Melanoma-bearing Mice |
| XIE Yan-fei1,2, CHEN Meng2, PENG Shu-hong1, TANG Xiao-tian2, SHU Qing-long1, ZUO Ai-ren1, CAO Rong-yue2 |
1. Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China;
2. Minigene Pharmacy Laboratory, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China |
|
|
|
Abstract To observe the anti-tumor activity of Mycobacterium tuberculosis Heat Shock Protein 65, the recombination protein HSP65 were expressed in E. coli and purified to mix with Freund’s adjuvant and then immunize two groups of C57BL/6J mice once a week for three times and seven times respectively. Two weeks after last immunization, B16-F10 melanomas cells were subcutaneous inoculated to investigate the anti-tumor effect of these vaccines. The results showed that mice immunized HSP65 three times had no significant anti-tumor effect with tumor inhibitory rate of 14.2% while when mice were pretreated with HSP65 seven times, its excised tumors were 73.2% smaller than those from control mice and the pathological section showed more focal necrosis and lymphocyte infiltration while less karyokinesis which implied the possible anti-tumor mechanism. However the precise mechanism still need more investigation.
|
|
Received: 30 November 2011
Published: 25 December 2012
|
|
|
|
|
[1] Kaufmann S H. Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-KDa protein. Eur J Immunol, 1987, 17(3):351-357.
[2] Davor L, Situmm A, Eterovic D, et al. Immunoprophylatic intraresical application of Bacillus Calmette-Guérin after transuretural resection of superficial bladlder cancer. Croat Med J, 2003,44:187-192.
[3] Rosenthal S R. Cancer precursors and their control by BCG. Dev Biol Stand, 1986, 58 ( Pt A):401-416.
[4] Brosman S A. Bacillus Calmette-Guerin immunotherapy: Techniques and results. Urol Clin North Am,1992,19(3): 557-564.
[5] Lamm D L, van der Meijden F M, Morales A, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial Bladder cancer. Urol, 1992,147(3):596-600.
[6] Maes H, Taper H, Cocito C. Comparison between Bacillus Calmette-Guerin and the A60 mycobacterial antigen complex used as cancer preventive immunotherapies. J Cancer Res Clin Oncol, 1996, 122(5): 296-300.
[7] Gaofu Q, Dan M, Jie W, et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine, 2004,22(23-24):3187-3194.
[8] Zugel U, Kaufmann S H E. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev, 1999,12(1):19-39.
[9] Srivastava P K, Udono H. Heat shock protein-peptide complexes in cancer immuntherapy. Curr Opin Immunol, 1994, 6: 728.
[10] Kissling R, Growbug A, Tvanyi J. Role of hsp60 during autoimmune and bacterial inflammation. Immunol Rev, 1991,121:91-111.
[11] Michaelsson J. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med, 2002,196(11):1403-1414.
[12] Abulafia-Lapid R, Elias D, Raz L, et al. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun, 1999,12(2):121-129.
[13] Szewezuk M R, Depew W T. Evidence for T lymphocyte reactivity to the 65 kilodalton heat-shock protein of mycobacteria in active Crohn’s disease. Clin Invest Med,1992,15(6): 494-505.
[14] Pockley A G. Heat shock proteins, inflammation, and cardiovascular disease. Circulation, 2002,105(8):1012-1017.
[15] Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002, 22(10):1547-1559.
[16] Ravagnan L, Gurbuxani S, Susin S A, et al. Heat-shock protein 70 antagonizes apoptosis inducing factor. Nat Cell Biol, 2001, 3(9): 839-843.
[17] Park K J, Gaynor R B, Kwak Y T. Heat shock protein 27 association with the I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-kappa B activation. J Biol Chem, 2003, 278(37): 35272-35278.
[18] Chen F, Chang R, Trivedi M, et al. Caspase proteolysis of desmin produces a dominant negative inhibitor of intermediate filaments and promotes apoptosis. J Biol Chem, 2003,278(9): 6848-6853. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
